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INTRODUCTION
Presently, the world’s population is in under tremendous 
pressure, due to COVID-19 pandemic. Worldwide, more 
than 90 million people are infected and among them more 
than 1.97 million people died till date (as per WHO). 
Deaths are increasing by leaps and bounds due to com-
munity transmission and the scientists are deliberately 
trying to find drugs from natural and synthetic origin 
to use as a potential antiviral agent. The entry of the 
COVID-19 virus into human cells is mediated via trans-
membrane spike (S) glycoprotein that contributes to the 
cell receptor binding, tissue tropism, and pathogenesis. 
Spike protein has conserved motifs have three domains 
namely S1, S2 and N. The S1-domain has a conserved 
receptor-binding domain (RBD), which recognizes the 
angiotensin-converting enzyme-2 (ACE-2) receptor (Bour-
gonje et al. 2019; Yao et al. 2020) which is the initial step 
of entry mechanism into the host cells (Walls et al. 2020; 
Wang et al. 2020). The expression of ACE-2 is higher in 
the intestinal epithelium and pulmonary pneumocytes 
than other tissues. The interaction of S protein and ACE-2 
results in imbalance of the renin-angiotensin system in 
the lungs as well as immunological intolerance, which 
leads to acute lung injury such as pulmonary oedema 
(Yao et al. 2020; Yang et al. 2007; Kuba et al. 2005). The 
entry of coronavirus into susceptible cells is a complex 
process that requires the concerted action of receptor 
binding and proteolytic processing of the S protein, 
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On-going global pandemic COVID-19 has spread all over the world and 
has led to more than 1.97 million deaths till date. Natural compounds may be useful to 
protecting health in this perilous condition. Mechanism of shuttle entry of SARS-COV-2 
virus is by interaction with viral spike protein with human angiotensin-converting enzyme-2 
(ACE-2) receptor. To explore potential natural therapeutics, 213 important phytochemi-
cals of nine medicinal plants Aconitum heterophyllum, Cassia angustifolia, Cymbopogon 
fl exuosus, Cymbopogon martinii, Nux vomica, Phyllanthus urinaria, Swertia chirayita, Justicia 
adhatoda, Vetiveria zizanioides were selected for in-silico molecular docking against the 
spike protein of SARS-COV-2 and compared with recently prescribed drug chloroquine, 
ramdesivir, lopinavir and hydroxychloroquine. Results revealed that rhamnocitrin of P. 
urinaria, 1,5-dihydroxy-3,8-dimethoxyxanthone of S. chirayita and laevojunenol of V. ziza-
nioides potentially binds with the receptor binding site of SARS-COV-2 spike glycoprotein 
and more robustly destabilized the RBD-ACE-2 binding over chloroquine, ramdesivir, 
lopinavir and hydroxychloroquine. It was also found that laevojunenol, rhamnocitrin, 
and 1,5-dihydroxy-3,8-dimethoxyxanthone qualifi ed the criteria for drug-likeness as per 
Lipinski rule. After attachment of the selected phytochemical with the spike protein the 
affi  nity of the later towards ACE-2 was minimized and the eff ect of 1,5-dihydroxy-3,8-
dimethoxyxanthone and laevojunenol was superior. Hence, rhamnocitrin of P. urinaria, 
1,5-dihydroxy-3,8-dimethoxyxanthone of S. chirayita and laevojunenol of V. zizanioides, 
are potential therapeutic molecules for SARS-COV-2, which upon binding with spike 
protein changes the affi  nity of the spike towards ACE-2 and therefore restrict the entry 
of the virus into a human cell. Subsequent clinical validation is needed to confi rm these 























# Both the authors contributed equally.
which endorses virus-cell fusion (Walls et al. 2020). In 
recent time, chloroquine, hydroxychloroquine, remdesivir, 
lopinavir, arbidol are drugs of choice for COVID treat-
ment but they have limitations and side effects (Wang et 
al. 2020; Cao et al. 2007; Rismanbaf et al. 2020; Yazdany 
et al. 2020). Under this emergency, several conventional 
and non-conventional medicines are being tested around 
the world to restrict viral transmission and to develop 
effective therapeutics. In this perspective, medicinal 
plants especially those employed in traditional medicine 
for the treatments of virus-allied symptoms have recently 
come under scientific surveillance as they contain bioac-
tive compounds that could be useful for development of 
potential drugs against COVID like viral diseases.
Since ancient human civilization, many phytochemi-
cals of diversified unique properties are being explored 
for customized treatments of variety of diseases owing 
to their analgesic, antipyretic, antioxidative, anticancer, 
immunomodulatory, anti-inflammatory, antimicrobial, 
anti-carcinogenic and many other notable properties 
( Jaiswal and Williams 2017; Suresh and Abraham 2020; 
Koparde et al. 2019). In global perspective, Lion’s share 
of the world population still depends on plant derived 
products to formulate drugs to treat their health problems. 
Some selective herbal products have low cytotoxicity and 
high bioavailability and are effective for the treatment of 
different viral diseases (Divya et al. 2020). The potential 
biological roles of plant’s secondary metabolites have 
now been explored in the blockage of virus particle’s 
entry, their multiplication and pathogenesis (ul Qamar 
et al. 2020). Among the different plants, P. urinaria (com-
monly called gripe weed) have potential ethnomedicinal 
importance against asthma, bronchitis, cough, tuber-
culosis, fever, influenza, digestive pain, conjunctivitis 
and anaemia. Besides, this plant also effective against 
hepatitis A-C, herpes and HIV (Singh 2018). S. chirayita 
(also is known as chirayta) is useful for the cure of different 
diseases and containing anti-inflammatory, antioxidant 
and antiviral compounds. S. chirayita has also very good 
antiviral activity against herpes and papilloma virus 
(Singh 2018; Kumar and Van Staden 2016). Likewise, V. 
zizanioides (vetivergrass; Hindi: Khas-Khas) used to treat 
many skin and nervous disorders and claimed to inhibit 
the dengue NS2B–NS3 virus (Lavanya et al. 2016). A. 
heterophyllum also helps in the treatment of common 
cold, flu, and malaria bronchitis, persistent cough and 
upper respiratory tract infections (Paramanick et al. 
2017). C. flexuosus commonly used against headaches, 
diabetes, rheumatism, hypertension, wounds, fever and 
bone fractures (Rajeswara Rao 2013). Nux vomica is used 
against colds and flu, particularly in the early stages of any 
virus infection (Singh 2018). These all plants are selected 
based on their ethno-botanical importance and the study 
of literature. The present study was aimed to explore the 
interaction of natural compounds of A. heterophyllum, C. 
angustifolia, C. flexuosus, C. martinii, N. vomica, P. urinaria, 
S. chirayita, J. adhatoda, V. zizanioides with the spike protein 
of the SARS-CoV-2 virus. The 3D structure of S protein 
was constructed and its binding ability against the 213 
phytochemicals of the above-mentioned medicinal plants 
were evaluated. The post binding effect of the conjugated 
spike protein with ACE-2 was also addressed in order 
to explore the effectiveness of natural compounds as 
potential anti-COVID drug. 
MATERIALS AND METHODS
Retrieval of protein sequence and prediction of homolo-
gous structure
The reference spike glycoprotein YP_009724390.1 se-
quence of human corona virus SARS-COV-2 collected 
from NCBI. Three-dimensional structure of corona viral 
spike glycoprotein (PDB ID: 6VSB) and human Angio-
tensin Converting Enzyme-2 (ACE-2) (PDB ID: 4APH) 
were retrieved from RCSB Protein Data Bank (https://
www.rcsb.org/) in PDB format and modelling of the 
spike glycoprotein (YP_009724390.1) was carried out 
in SWISS-MODEL server (Waterhouse et al. 2018) and 
further analysed by using PyMol (DeLano 2002). Quality 
assessment of this spike glycoprotein model was validated 
by PROCHECK by analysing the Ramachandran plot 
(Laskowski et al. 1993).
Retrieval of ligands structure 
Three-dimensional structure of 213 natural compounds 
of A. heterophyllum, C. angustifolia, C.flexuosus, C. martinii, 
N. vomica, P. urinaria, S. chirayita, J. adhatoda, V. zizanioides 
and drugs remdesivir, lopinavir, chloroquine and hydroxy-
chloroquine was retrieved from Indian Medicinal Plants, 
Phytochemistry and Therapeutics (IMPPAT) database 
(Mohanraj et al. 2018), PubChem (Kim et al. 2016) on the 
basis of literature survey and listed in Table 1-3.
Protein-ligand docking
Prior docking, the water molecules were removed from the 









No Compound names Plant species Binding energy (kcal/mol) H-bond interaction
1 Hetidine A. heterophyllum -9.7 371
2 Isoatisine A. heterophyllum -8.7 -
3 Hetisinone A. heterophyllum -8.6 370, 489
4 Veratridine A. heterophyllum -8.5 115, 167
5 6-benzoylheteratisine A. heterophyllum -8.4 377, 379
6 Hetisine A. heterophyllum -8.4 370
7 Atidine A. heterophyllum -8.3 377, 379, 457
8 Beta-carotene A. heterophyllum -8.3 -
9 Atisine A. heterophyllum -8.2 455
10 Dihydroatisine A. heterophyllum -8.1 338, 339
11 Aricine A. heterophyllum -8 370, 457
12 Benzoylmesaconine A. heterophyllum -8 488
13 Lactone atisenol A. heterophyllum -8 457
14 Lappaconitine A. heterophyllum -7.6 357, 473, 475
15 6-acetylheteratisine A. heterophyllum -7.4 379
16 Heterophyllisine A. heterophyllum -7.4 489
17 Aconitine A. heterophyllum -7.3 -
18 Anisoylaconine A. heterophyllum -7.3 377, 457, 473
19 Hypaconitine A. heterophyllum -7.3 371, 373
20 Mesaconitine A. heterophyllum -7.3 371, 373
21 Phytosterols A. heterophyllum -7.3 457
22 Jesaconitine A. heterophyllum -7.2 165, 355
23 Isorhamnetin 3-gentiobioside C. angustifolia -8.4 369, 417, 457, 487, 489, 493
24 Kaempferol C. angustifolia -8.1 457, 477
25 Aloe-emodin C. angustifolia -7.7 457, 477
26 Tinnevellinglucoside C. angustifolia -7.6 371, 403, 409, 505
27 Sennaglucosides C. angustifolia -9.8 343, 370, 371, 453, 476, 478, 493 
28 Emodin-8-glucoside C. angustifolia -8.9 369, 371, 375, 376, 405, 406, 409
29 Rhein C. angustifolia -8.6 -
30 Isorhamnetin C. angustifolia -8.6 457, 477
31 Arundoin C. flexuosus -8.7 -
32 Phytosterols C. flexuosus -7.8 457
33 Humulene C. flexuosus -7.5 457
34 Caryophylene oxide C. martinii -7 478
35 Stryvomicine A N. vomica -9.2 -
36 Beta-colubrine chloromethochloride N. vomica -8.8 457, 477
37 Alpha-colubrine chloromethochloride N. vomica -8.5
38 Oleanolic acid P. urinaria -8.7 370, 457
39 Trans-8,9-Dihydro-benz(a)anthracene-8,9-diol P. urinaria -8.7 -
40 Corilagin P. urinaria -8.7 379, 457, 487, 493
41 Naringin P. urinaria -8.7 343, 375, 403, 405, 437
42 Furosin P. urinaria -8.7 417, 456, 457, 493, 494
43 Kaempferol 7-methyl ether 4'-glucoside P. urinaria -8.7 417, 456, 457, 493, 494
44 Gallocatechingallate P. urinaria -8.6 457
45 Ellagic acid P. urinaria -8.5 371, 405, 408, 409
46 Cleistanthol P. urinaria -8.4 -
47 Quercetin P. urinaria -8.4 371, 455, 457, 477
48 Daucosterol P. urinaria -8.4 377, 488
49 Spruceanol P. urinaria -8.3 457, 490
50 Quercitrin P. urinaria -8.3 457, 488
Table 2. List of natural plant derived compounds whose binding energy is higher than -7 kcal/mol when binds with SARS-COV-2 spike glycoprotein.
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No Compound names Plant species Binding energy (kcal/mol) H-bond interaction
51 13-Methyl-6,7,8,9,11,12,14,15,16,17-
decahydrocyclopenta[a]phenanthrene-3,17-diol
P. urinaria -8.2 -
52 Betulinic acid P. urinaria -8.2 408, 456, 457
53 Epigallocatechingallate P. urinaria -8.2 369, 379, 457, 487, 490
54 Rutin P. urinaria -8.2 372, 374, 375, 403, 405, 437, 439, 
453, 505
55 Epicatechin-3-gallate P. urinaria -8.1 381, 417, 457, 487, 489
56 Beta-sitosterol P. urinaria -8.1 -
57 Glochidiol P. urinaria -8 408
58 Epicatechin P. urinaria -7.9 379, 381, 487, 489
59 Epigallocatechin P. urinaria -7.9 379, 381, 487, 489
60 Betulin P. urinaria -7.9 456, 457
61 Rhamnocitrin P. urinaria -7.9 379, 487, 489
62 Brevifolincarboxylic acid P. urinaria -7.8 375, 377, 415
63 Ethyl brevifolincarboxylate P. urinaria -7.5 371, 457, 477
64 Digallic acid P. urinaria -7.4 370, 457, 477, 478
65 Methyl brevifolincarboxylate P. urinaria -7.3 455, 457, 490
66 Urinatetralin P. urinaria -7.1 381
67 Episwertenol S. chirayita -9.7 -
68 Hopenol B S. chirayita -9.3 -
69 Erythrodiol S. chirayita -9.1 -
70 Friedlein S. chirayita -9.1 357
71 Chiratenol S. chirayita -8.9 -
72 Kairatenol S. chirayita -8.7 -
73 Swertanone S. chirayita -8.7 -
74 Oleanolic acid S. chirayita -8.6 -
75 Taraxasterol acetate S. chirayita -8.5 378, 408
76 Swertenol S. chirayita -8.3 466
77 Amarogentin S. chirayita -8.2 370, 371, 372, 457, 490
78 Swertiapuniside S. chirayita -8.1 372, 403, 439, 505, 506
79 Ursolic acid S. chirayita -8.1 457
80 1,8-Dihydroxy-2,6-dimethoxy-9H-xanthen-9-one S. chirayita -7.9 -
81 Mangiferin S. chirayita -7.9 379, 456, 457, 492
82 1,5-dihydroxy-3,8-dimethoxyxanthone S. chirayita -7.7 406, 409, 417
83 Swertianin S. chirayita -7.6 415, 377, 369
84 Decussatin S. chirayita -7.5 457, 477
85 Demethylbellidifolin S. chirayita -7.5 409
86 Isobellidifolin S. chirayita -7.5 371, 457
87 Swerchirin S. chirayita -7.5 371, 457
88 7,11-Epoxy-eremophila-1,9-dien-8-α-ol V. zizanioides -8.2 457
89 Eudesmane V. zizanioides -8 -
90 Cadalene V. zizanioides -7.9 -
91 Khusene V. zizanioides -7.9 -
92 10-epi-Acora-3,11-dien-15-al V. zizanioides -7.8 457, 478
93 Beta-vetivone V. zizanioides -7.8 457
94 15-nor-prezizaan-7-one V. zizanioides -7.7 457, 478
95 Isokhusimol V. zizanioides -7.7 457
96 Isovalencenol V. zizanioides -7.7 457, 477
97 Khusiol V. zizanioides -7.7 -
98 (1S,2S,8R)-2,6,7,7-tetramethyltricyclo[6.2.1.01,5]
undecane




three-dimensional structure of the spike glycoprotein. The 
molecular docking study was performed for exploration 
of the binding affinity of the spike glycoprotein with the 
213 selected natural phytochemicals in addition with rem-
desivir, lopinavir, chloroquine and hydroxychloroquine 
through AutoDock Vina [version 1.1.2] (Trott and Olson 
2010). SARS-COV-2 spike protein S1 domain chains (A, 
B, C) have common reference active site of K417, G446, 
Y449, F486, N487, Y489, Q493, Q498, T500, N501, G502, 
Y505 (Walls et al. 2020; Wang et al. 2020; Yan et al. 2020; 
Lan et al. 2020). These sites were initially targeted for 
grid based molecular docking study with the selected 
natural phytochemicals. The grid box dimensions were 
68 Å × 90 Å × 58 Å with a spacing of 1 Å and center set at 
coordinate 219.172, 224.276 and 287.134 in x, y, and z axis, 
respectively, centring around the ACE-2 binding domain. 
An array of ligands was screened based on binding en-
ergy at active site amino acid residues, and subsequently 
blindly docked with SARS-COV-2 spike protein using 
AutoDock with new grid dimension to cover the whole 
spike glycoprotein. The grid coordinate considered as 126 
Å × 126 Å × 126 Å with a spacing of 1 Å and center set to 
coordinate 211.921, 226.209 and 247.631 in the x, y and 
z axis with 24 exhaustiveness, respectively. During blind 
docking, the size of grids was kept at maximum covering 
the whole surface of the protein to allow the ligand to 
bind in an unbiased binding pocket. Polar H charges of 
the Gasteiger-type were assigned to the receptor molecule 
and torsions were detected. Default settings of AutoDock 
Vina were used for docking studies.
No Compound names Plant species Binding energy (kcal/mol) H-bond interaction
99 Acora-2,4-diene V. zizanioides -7.6 -
100 Beta-cadinene V. zizanioides -7.6 -
101 Beta-vetivenene V. zizanioides -7.6 -
102 Khusimone V. zizanioides -7.6 -
103 Khusinol oxide V. zizanioides -7.6 478
104 7,15-epoxyprezizaane V. zizanioides -7.5 370
105 10-epi-Acor-3-en-5-one V. zizanioides -7.5 -
106 Allo-khusiol V. zizanioides -7.5 370
107 Alpha-vetispirene V. zizanioides -7.5 -
108 Eremophilane V. zizanioides -7.5 -
109 Khusilal V. zizanioides -7.5 457
110 Khusinodiol V. zizanioides -7.5 457
111 Khusitone V. zizanioides -7.5 -
112 13-nor-Eudesm-5-en-11-one V. zizanioides -7.4 457
113 Cedrane V. zizanioides -7.4 -
114 Epizizanal V. zizanioides -7.4 -
115 Isovetiselinenol V. zizanioides -7.4 -
116 Khusinol V. zizanioides -7.4 490
117 Laevojunenol V. zizanioides -7.4 489
118 11,12,13-tri-nor-cis-Eudesm-5-en-7-one V. zizanioides -7.3 -
119 Beta-Vetispirene V. zizanioides -7.3 -
120 Isokhusenic acid V. zizanioides -7.3 -
121 Isokhusinol oxide V. zizanioides -7.3 489
122 Nootkatone V. zizanioides -7.3 -
123 Cadin-4-en-10-ol V. zizanioides -7.2 -
124 Khusimol V. zizanioides -7.2 -
125 Ac1lb1ow V. zizanioides -7.1 -
126 Alpha-vetivone V. zizanioides -7.1 -
127 Cyclocopacamphenol V. zizanioides -7.1 457, 477
128 Epizizanone V. zizanioides -7.1 -
129 Khusol V. zizanioides -7.1 370
Table 2. Continued.
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No Compound names Plant species Binding energy (kcal/mol)
1 Phytosterols A. heterophyllum -6.9
2 Delphatines A. heterophyllum -6.7
3 Lycoctonine A. heterophyllum -6.6
4 Dl-borneol C. flexuosus -6
5 Citronellal C. flexuosus -5.7
6 Citral C. flexuosus -5.7
7 Methyleugenol C. flexuosus -5.6
8 Myrcene C. flexuosus -5.1
9 6-Methylhept-5-en-2-ol C. flexuosus -5
10 Triacontane C. flexuosus -4.9
11 Decanal C. flexuosus -4.8
12 Trans-2-Hepten-1-ol C. flexuosus -4.5
13 Beta-caryophyllene C. martinii -6.6
14 3-carene C. martinii -6.5
15 Carvylacetate C. martinii -6.4
16 P-cymene C. martinii -6.3
17 Alpha-terpineol C. martinii -6.3
18 Dihydrocarvone C. martinii -6.3
19 (-)-3-carene C. martinii -6.3
20 Beta-terpineol C. martinii -6.2
21 Perillyl alcohol C. martinii -6.2
22 D-carvone C. martinii -6.2
23 (-)-cis-carveol C. martinii -6.1
24 Cis,cis-farnesol C. martinii -6.1
25 Alpha-farnesene C. martinii -6.1
26 Limonene C. martinii -5.9
27 Eucalyptol C. martinii -5.8
28 Dihydrocarveol C. martinii -5.7
29 Geranyl acetate C. martinii -5.6
30 Geraniol C. martinii -5.3
31 6-Methyl-5-hepten-2-one C. martinii -5.2
32 6-Octen-1-ol, 3,7-dimethyl-, (R)- C. martinii -5.2
33 Geranyl butyrate C. martinii -5.1
34 (-)-Linalool C. martinii -4.9
35 2-Nonanol C. martinii -4.7
36 1,5-Hexadiyne J. adhatoda -5.4
37 2-(2,5-Hexadiynyloxy)tetrahydro-2H-pyran J. adhatoda -5.2
38 Heptasiloxane,1,1,3,3,5,5,7,7,9,9,11,11,13,13-tetradecamethyl- J. adhatoda -5.1
39 Hexasiloxane,1,1,3,3,5,5,7,7,9,9,11,11-dodecamethyl- J. adhatoda -4.7
40 Octasiloxane,1,1,3,3,5,5,7,7,9,9,11,11,13,13,15,15-hexadecamethyl- J. adhatoda -4.3
41 Pentasiloxane,1,1,3,3,5,5,7,7,9,9-decamethyl- J. adhatoda -4.3
42 Nirtetralin P. urinaria -6.9
43 Phyltetralin P. urinaria -6.9
44 Lintetralin P. urinaria -6.8
45 Hypophyllanthin P. urinaria -6.7
46 Syringin P. urinaria -6.7
47 Virgatusin P. urinaria -6.7
48 Dehydrochebulic acid trimethyl ester P. urinaria -6.6
49 Ferulic acid P. urinaria -6.5
50 5-demethoxyniranthin P. urinaria -6.5
Table 3. List of natural plant derived compounds whose binding energy is less than -7 kcal/mol when binds with SARS-COV-2 spike glycoprotein.
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Lipinski rule for validation of drug-likeness
Lipinski’s rule of 5 helps to find out drug likeness of any 
experimental compound. Five rules are (i) molecular 
mass of the drug should be less than 500 Dalton, (ii) high 
lipophilicity (expressed as LogP less than 5), (iii) less than 
5 hydrogen bond donors, (iv) less than 10 hydrogen bond 
acceptors, (v) molar refractivity should be between 40-130. 
The predictable drugs sites Lipinski Rule were checked 
by using SCFBio web-based database (Lipinski 2004).
Protein-protein docking
Spike glycoprotein (in free form and complex with selected 
phytochemicals) (Table 4) and ACE-2 were considered for 
protein-protein docking with receptor-binding domain 
(RBD) of the spike glycoprotein (S1 subunit) using HDOCK 
server (Yan et al. 2020). Precisely, the 19-41 amino acid 
resides of ACE-2 was employed for the docking with 417-
505 amino acids of spike glycoprotein S1 subunit. In total, 
four ACE-2 docking experiments were performed with 
spike glycoprotein as per specification stated in Table 4.
RESULTS AND DISCUSSION
Homologous structure prediction of spike glycopro-
tein and its validation
The study of molecular docking and the ligand-based 
No Compound names Plant species Binding energy (kcal/mol)
51 Cucurbic acid P. urinaria -6.3
52 Methyl gallate P. urinaria -6.2
53 Niranthin P. urinaria -6.2
54 4-O-Methylgallic acid P. urinaria -6
55 Phyllanthin P. urinaria -5.9
56 (6r)-menthiafolic acid P. urinaria -5.9
57 4-hydroxybenzaldehyde P. urinaria -5.7
58 5-hydroxymethylfurfural P. urinaria -4.6
59 Dl-tryptophan S. chirayita -6.9
60 Gentianine S. chirayita -6.6
61 Enicoflavine S. chirayita -5.5
62 Dl-arginine S. chirayita -5.2
63 Nonacosyl_hentriacontanoate S. chirayita -5
64 Octadecanoate S. chirayita -4.8
65 Glutamate S. chirayita -4.2
66 Amorphane V. zizanioides -7
67 6,12-Epoxy-elema-1,3-diene V. zizanioides -6.9
68 13-nor-4,5-Epoxyeudesm-6-en-11-one V. zizanioides -6.9
69 Bisabolane V. zizanioides -6.7
70 3-carene V. zizanioides -6.5
71 15-nor-Funebran-3-one V. zizanioides -6.5
72 Beta-pinene V. zizanioides -6.5
73 Cis-Isoeugenol V. zizanioides -6.5
74 Cyclocopacamphan-12-al V. zizanioides -6.5
75 Isobisabolene V. zizanioides -6.5
76 Nootkatol V. zizanioides -6.4
77 Alpha-terpineol V. zizanioides -6.3
78 2-Methoxy-4-vinylphenol V. zizanioides -5.8
79 4-vinylphenol V. zizanioides -5.8
80 Eucalyptol V. zizanioides -5.8
81 Eugenol V. zizanioides -5.6
82 O-cresol V. zizanioides -5.5
83 M-cresol V. zizanioides -5.4
84 Oleamide V. zizanioides -5
Table 3. Continued.
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computer-aided drug discovery approach involves energy, 
affinity and three-dimensional structural conformations-
based analysis of ligands interaction with the target of 
interest. The binding ability of a ligand molecule to a 
specific target site depends on occurrence of proper cleft, 
proper hydrogen bonding and the nature of residues 
present at the target site and their interactive energy bal-
ance (Tripet et al. 2004). The binding affinity of a ligand 
for a targeted receptor is measured by binding energy. 
Lower binding energy implies that binding affinity is 
high whereas higher energy endorses the reverse (Zhou 
et al. 2020). In the present study, three-dimensional (3D) 
homologous structure of spike glycoprotein was generated 
from the reference protein sequence (YP_009724390.1) 
using the cryo-EM structure (6VSB) through SWISS-
MODEL server and further analyzed through PyMol. 
PyMol is a molecular visualization tool; used here to align 
the predicted three-dimensional structure of the spike 
glycoprotein of SARS-CoV-2 into the cryo-EM structure 
of 6VSB. The Root-mean-square deviation (RMSD) of this 
model was computed as 0.278Å. Further, the predicted 
3D structure was validated through RAMACHANDRAN 
plot using PROCHECK. The result revealed that 85.9% 
belongs to the most favourable region, 12.2% in allowed 
region, 1.6% in the generously allowed region, and only 
0.3% in disallowed region (Fig. 1). Though cryo EM 
structure of SARS-COV-2 spike glycoprotein (6VSB) was 
available, some amino acids were not resolved properly 
at different locations due to its 3.46 Å resolution. To get 
the complete structure of spike, homology modelling was 
performed. Good quality structure with 98.1% residues 
at ordered form indicated the proper conformational 
packaging of protein. 
Assessment of binding affi  nity of 213 ligands with spike 
protein and their subsequent screening
A spike glycoprotein of SARS-COV-2 has three domains 
namely S1, S2 and N. The S2 domain intercedes the 
membrane fusion process and the S1 domain utilizes 
human angiotensin-converting enzyme-2 (hACE-2) as 
the receptor to infect human cells (Pandey et al. 2020). 
The literature review revealed that the receptor-binding 
domain (RBD) of the S1 subunit of spike protein binds 
with the target cell ACE-2 receptor and forms the RBD-
ACE-2 complex. According to recent report, ACE-2 could 
mediate SARS-CoV-2 binding by spike protein key resi-
dues of K417, G446, Y449, F486, N487, Y489, Q493, Q498, 
T500, N501, G502, Y505 (Walls et al. 2020; Wang et al. 
2020; Yan et al. 2020; Lan et al. 2020). In this in-silico 
study, we attempted to explore the binding affinity of 
213 phytochemicals in addition to remdesivir, lopinavir, 
chloroquine and hydroxychloroquine with the active site 
residues of the spike glycoprotein (Fig. 2A). The selection 
of the natural ligands of plant origin was primarily made 
on the basis of (i) minimal binding energy (<-7 kcal/mol) 
and (ii) formation of at least one H-bond with the active site 
residues (417-505) in the S1 subunit of the spike glycopro-
tein. These criteria were fulfilled by 23 compounds which 
were further blindly docked with whole spike glycoprotein 
Molecular docking complex HDOCK score RMSD value
Spike glycoprotein dock with ACE2 -360.86 0.51
Spike glycoprotein and rhamnocitrin dock with ACE2 -360.86 0.51
Spike glycoprotein and 1,5-dihydroxy-3,8-dimethoxyxanthone dock with ACE2 -243.15 481.28
Spike glycoprotein and laevojunenol dock with ACE2 -238.13 480.02
Table 4. Diff erent complex of spike glycoprotein (free and ligand bound) and ACE2 docking in HDOCK and their binding score.




(Table 1-2) to analyze the affinity of selected molecules at 
the active site of spike glycoprotein (417-505) instead of 
other cleft and pockets. It was evident that rhamnocitrin 
of P. urinaria, 1,5-dihydroxy-3,8-dimethoxyxanthone of 
S. chirayita, laevojunenol and khusinol of V. zizanioides are 
capable to bind with active site residues of the S1 subunit 
of spike glycoprotein (S) in 0 (zero) RMSD pose (Fig. 2). 
So, these three phytochemicals are the best ligand mol-
ecules for spike protein active site which restricts smooth 
interaction between spike and ACE-2.
The molecular docking study of spike protein with 
remdesivir revealed that this drug has the capability to 
bind with S1 domain through H-bond with the ARG403, 
ASP405 and ARG408 of B and PHE374, SER375 and 
TYR508 of C chain with binding energy of -8.1 kcal/
mol. However, though remdesivir binds with the spike 
protein at S1 domain, but the site of attachment is not 
the active site of spike protein. Lopinavir interacts with 
the S2 subunit through amino acid residues GLN957, 
THR961 and associated with binding energy of -11.8 
kcal/mol. Alongside, it was also revealed that chloroquine 
and hydroxychloroquine binds with LEU455, GLY485, 
PHE490,PRO491 and PRO559, PHE855, THR573, ILE587 
residues of S2 domain having the binding energy of -6.7 
and -6.3 kcal/mol, respectively (Table 3). It is evident that 
among the four drugs neither one is capable to bind at 
active site of spike glycoprotein.
The docking results were analysed based on a combi-
nation of binding energy, clustering score, shape comple-
mentarity, functional significance of the binding pocket 
and favourable interactions including H bonds.









300.26 3 6 2.2 77.272881
1,5-dihydroxy-3,8-dimethoxyxanthone B/GLU-406, B/GLN-409,
B/LYS-417
288.26 2 6 2.37 77.145782
Laevojunenol B/TYR-489 222.37 1 1 3.78 77.145782
Table 5. Physicochemical properties of natural plant derived compounds and their binding energy during molecular docking. Diff erent capital 
alphabets before amino acids indicate diff erent polypeptide chains.
Figure 2. Binding of (A) remdesivir, lopinavir, chloroquine and hydroxychloroquine and (B) rhamnocitrin, 1,5-dihydroxy-3,8-dimethoxyxanthone, 
laevojunenol and khusinol with SARS-CoV-2 spike glycoprotein.
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Validation of drug-likeness
Lipinski rule of five is a rule of thumb to check the drug's 
likeness of any chemical compound. It acts as a filter to 
screen potential therapeutic agents/drugs just at the initia-
tion of the program, thereby minimizing the labour and 
costs of clinical drug development and to a large extent 
prevents late-stage clinical failures (Raj et al. 2019; Pandey 
et al. 2020). In this study, three selected phytochemicals 
were examined for their drug-likeness in the light of 
the rules (Table 5). The results clearly demonstrated that 
rhamnocitrin, 1,5-dihydroxy-3,8 dimethoxyxanthone 
and laevojunenol qualified the rule.
Ligand binding eff ect analysis on spike glycoprotein-
ACE-2 interaction
Finally, the selected drugs were individually used to study 
effective inhibition of RBD-ACE2 complex formation. The 
interaction of spike glycoprotein with ACE-2 is depicted 
in Fig. 3. In order to verify the possible effect of the ligands 
in spike-ACE-2 interaction, the S glycoprotein-ligand 
docked complexes were further docked with ACE-2 
protein in HDOCK web server. HDOCK is a web server-
based protein-protein and protein-DNA/RNA docking 
tool. This web server based molecular docking revealed 
that the binding energy of spike protein-ACE-2 interac-
tion was –360.86 and rmsd value 0.51 which decreased 
to -243.15 and 481.28 rmsd for 1,5-dihydroxy-3,8-di-
methoxyxanthone, -238.13 and 480.02 for laevojunenol, 
-360.86 and 0.51 for rhamnocitrin separately pre-fixed 
with spike glycoprotein, respectively. Apart from the 
effect on binding energy, it was also evident that the 
binding of 1,5-dihydroxy-3,8-dimethoxyxanthone and 
laevojunenol triggers the shifting of interaction sites 
of both the partners from their active sites which may 
hamper the viral entry into human cell (Fig. 4). Also 
1,5-dihydroxy-3,8-dimethoxyxanthone of S. chirayita, 
laevojunenol of V. zizanioides binding pose being poor, 
these compounds can be considered as potential inhibitor 
of S-glycoprotein and human ACE-2 interaction.
CONCLUSION
In conclusion, we can state that the present computer-aided 
in-silico study of exploration of preventive drugs against 
COVID-19 revealed that natural herbal phytochemicals 
like rhamnocitrin; 1,5-dihydroxy-3,8-dimethoxyxanthone 
and laevojunenol of P. urinaria, S. chirayita, and V. zizanioides 
have immense potential to restrict the onset of SARS-
COV-2 disease due to their ability to interrupt the normal 
viral spike protein and ACE-2 interaction upon binding 
to the spike protein. The potential of 1,5-dihydroxy-3,8-
dimethoxyxanthone and laevojunenol was proved to be 
superior. Maybe these compounds will be useful as po-
tential preventive drugs, however, further experiments 
are necessary to validate their effects.
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